Phase 3 Readout

ADMA: Phase 3 Topline: Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early Sta

Name: Phase 3 Topline: Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early Sta
Start: 2039-07-15
End: 2039-07-15

July 15, 2039. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: July 15, 2039
Company: ADMA BIOLOGICS, INC. (ADMA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early Sta

July 15, 2039

ADMA overview →

Company: ADMA BIOLOGICS, INC. (ADMA)
Indication: Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Lung Non-Small Cell Carcinoma